// App-Quantinova.ai

2041 : Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: Preliminary results from phase I study.

Researchers

Presenter

  • Solmaz Sahebjam

Principal Investigators

  • Peter A. Johnstone

  • Peter A. J. Forsyth

  • John Arrington

  • Frank D Vrionis

  • Arnold B Etame

  • Nam D. Tran

  • Pranali H Dalvi

  • Sungjune Kim

  • Robert J Macaulay

  • Prakash Chinnaiyan

  • Michael Yu

Medical Centers

  • Moffitt Cancer Center, Tampa, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Beaumont Health System, Dearborn, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Anaplastic astrocytoma

  • Glioblastoma

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Bevacizumab

Outcome

  • Unknown

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02313272

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved